Background. Recently, a Japanese model used to predict 10-year risk of end-stage renal disease (ESRD) in IgA nephropathy (IgAN) patients was published. We tested the applicability of the Japanese model in predicting 10-to 20-year risk of ESRD and all-cause mortality in a cohort of Norwegian IgAN patients. Methods. A cohort of IgAN patients (1988IgAN patients ( -2004 were identified in the Norwegian Kidney Biopsy Registry (NKBR) and ESRD or death during follow-up through Results. In eight of the nine risk groups, representing 597/633 (94%) of the patients in our cohort, the observed 10-year risk was within or close to the expected 10-year risk of ESRD. ESRD occurring after >10 years of observation was most frequent in the groups with 5-30% expected risk at 10 years of follow-up. A close association between risk of ESRD and risk of death prior to ESRD was observed.
Introduction
IgA nephropathy (IgAN) is probably the most frequently occurring primary glomerulonephritis worldwide [1] [2] [3] [4] . Although most patients with primary IgAN are considered to have a good long-term prognosis, a substantial fraction of these patients progress to end-stage renal disease (ESRD) after years of follow-up [5] [6] [7] . Well-known clinical and histopathological risk factors indicating progressive renal disease have, for decades, been thoroughly studied and a large number of different risk factors for development of ESRD in IgAN patients are identified and many are well established in clinical practice [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . There is, nevertheless, an ongoing debate on which risk factors are most important. Different combinations of clinical and morphological factors have been used to identify patients at high risk for development of ESRD, patients who probably need a closer follow-up than less severely affected individuals [8, [14] [15] [16] [17] .
Recently, a new scoring system to quantitatively predict 10-year risk of ESRD among IgAN patients was published based on a large Japanese cohort of 2238 IgAN patients [18] . This scoring system reliably separated patients into nine different risk groups for ESRD. Although IgAN is also the most frequently occurring primary glomerulonephritis in Japan, a limitation of the Japanese scoring system for IgAN is that it was developed solely among Japanese patients and its applicability in other races can be questionable. A second limitation is that many IgAN patients develop ESRD after >10 years of disease indicating that the 10-year risk may deviate substantially from the clinically more relevant life time risk of ESRD [8, 12] . Finally, whether the Japanese scoring system for IgAN also predicts risk of deaths prior to ESRD is uncertain.
We regard the Japanese scoring system as a potentially useful prognostic tool both in care of and research on IgAN patients. Because of its limitations we decided to test its applicability on a cohort of 633 Norwegian, predominately Caucasian, IgAN patients identified in the Norwegian Kidney Biopsy Registry (NKBR) and with a follow-up period ranging up to 20 years. Our working hypothesis is that the Japanese scoring system is applicable to predict both 10-year risk of ESRD and risk of death prior to ESRD in Norwegian IgAN patients. We also hypothesized that risk of ESRD, at least in some risk groups of IgAN patients, is substantially higher after 20 years of follow-up than after 10 years.
Materials and methods
The study was approved by the local ethics committee, The Norwegian Social Science Data Services and The Norwegian Data Inspectorate.
Registries used in the present study
The Kidney Biopsy Registry was established in 1988 and has registered clinical, biochemical, immunological and morphological data from most patients who have had a kidney biopsy performed in Norway (population of 4.8 million) since 1988. All kidney biopsies were evaluated by an experienced nephropathologist at the Gade Institute at Haukeland University Hospital in Bergen.
The Norwegian Renal Registry is located at Oslo University Hospital, Rikshospitalet, Norway. All patients in Norway starting renal replacement therapy (RRT) have been registered since 1980.
The Norwegian Population Registry is a part of the tax office in Norway and deaths among Norwegian citizens are registered on a weekly basis.
Identification of patients with IgAN
We identified from the Kidney Biopsy Registry all patients diagnosed with IgAN in the period from 1988-2004. The diagnosis of IgAN was based on the criteria listed in the World Health Organization monograph of renal disease and the typical morphological findings were mesangioproliferative changes with deposits of IgA.
Identification of IgAN patients with ESRD
A record linkage between the cohort of patients with IgAN in the NKBR and the Norwegian Renal Registry was done using the unique Norwegian 11 digit personal identification number making the linkage easy and reliable. We identified all patients with IgAN who had developed ESRD by the end of 2008.
Identification of IgAN patients with death prior to ESRD
A record linkage between the cohort of patients with IgAN and the Population Registry of Norway was done using the same personal identification number making the linkage easy and reliable. We identified all patients that had died by the end of 2008. Deaths occurring after ESRD were not included in our analysis.
Definition of primary and secondary end points
The primary end point of the present study was ESRD defined as commencement of RRT. Secondary end points were death prior to commencement of RRT.
Definition of observation period
The observation periods were defined as the period between the date of the kidney biopsy and commencement of ESRD, death or end of 2008 whatever came first.
The Japanese scoring system
The Japanese scoring system for IgAN is described in [18] and shown in Table 1 .
Adjustments of the scoring system
Due to lack of data regarding the number of red blood cells/high power field in the Kidney Biopsy Registry, we had to modify the risk factor of mild haematuria. We defined mild haematuria as haemoglobin 11 or 21 on urine dipstick test.
We used the modified Modification of Diet in Renal Disease formula (Caucasians) to calculate glomerular filtration rate (GFR) instead of the revised equation for estimated GFR from serum creatinine in Japan that was used in the Japanese scoring system.
Histological data
The biopsies were not initially scored according to the Japanese histological grading system (Grades 1-4) for IgAN, but the essential histological parameters included in it are registered in the Norwegian Kidney Biopsy. The following findings distinguishes between Grades 1-2 versus Grades 3-4 in the Japanese histological grading system and they were also used in the present study; presence of glomerulosclerosis, crescent formation or adhesion to Bowman's capsule in >10% of glomeruli and/or prominent changes in interstitium and/or blood vessels.
Missing data
Data on serum albumin in the Kidney Biopsy Registry are not available for all patients. In such cases, we imputed 0 points on this risk parameter. Consequently, in some of these cases, classification into a higher risk group would be correct if true serum albumin was known and <4.0 g/dL. As a statistical safety analysis, we analysed the applicability of the Japanese scoring system of IgAN after exclusion of these patients.
Analysis and statistical methods
With the adjustments mentioned in the previous section, we applied the Japanese scoring system of IgAN on all patients in our cohort. Life tables and Kaplan-Meier survival curves were generated for all nine risk groups, as defined in the Japanese scoring system, and 10, 15, 17.5 and 20 years cumulative risk of ESRD and death prior to ESRD were recorded. We compared the observed 10-year risk of ESRD in each separate group with the expected, as defined in the Japanese scoring system.
To investigate whether the nine risk group Japanese prognostic system could be simplified without loss of statistical significant information, we did a comparison of the Kaplan-Meier plots illustrating cumulative risk of ESRD in each risk group using log-rank test, and risk groups that were not significantly different from each other were merged. We then repeated the analysis on cumulative risk of ESRD and death prior to ESRD on the new risk groups.
We used Cox regression statistics to calculate the 10-year hazard ratio (HR) of ESRD for all risk factors included in the prognostic model. HR unadjusted, after adjustment for estimated glomerular filtration rate (eGFR) and after adjustment for all factors in the scoring system were registered. Finally, we used Cox regression statistics to calculate the HR of death prior to ESRD in patients with initial eGFR less than versus higher than 60 mL/min/1.73m 2 after adjustment for age and gender.
Results
A total of 633 patients, 467 males (74%), with IgAN were identified and 146 (23%) of these patients developed ESRD, 121 after <10 years of follow-up. In the present study, 45 patients died prior to development of ESRD. Mean observation period was 10.3 years, range 0-20.8 with a total of 6520 observation years. Mean age at start of observation period was 39 years (SD 16), eGFR 67 mL/min/1.73m 2 (SD 30), systolic blood pressure 138 (SD 22) and serum albumin was 3.9 g/dL. Positive dipstick for protein (!21) was present in 333 (53%) patients. Further details regarding cohort characteristics are given in Table 2 .
The results after scoring of all 633 patients are shown in Table 3 . The observed 10-year cumulative risk of ESRD was within the expected range in Risk groups 1, 2, 3, 4, 6 and 7 covering 482 (76%) of the cohort. In Risk groups 5 and 9, the observed cumulative risk of ESRD was only slightly lower than the expected risk (19.2 versus 20-30% and 87.7 versus 90-100%). Additionally, in Risk group 9, the observed cumulative risk rose to 90.8% after 10.3 years observation. Thus, only 36 patients (6% of the cohort) in Risk group 8 had an observed cumulative risk of ESRD substantially outside the expected range, 42.0 versus 70-90%. Also, in this group, the observed cumulative risk of ESRD increased substantially, 57.8% after 10.6 years of observation.
In summary, the observed cumulative risk of ESRD was within or only slightly outside the expected range in 597 patients (94%) of the cohort.
When comparing the cumulative risk of ESRD at 10 years and at the last point of follow-up (Table 3) , a distinct pattern appeared. In the two groups with the most favourable prognosis (<5% expected 10 years risk of ESRD) and in the four groups with poorest prognosis (>30% expected 10 years risk of ESRD), the latest cumulative risk stayed within the range expected after 10 years. In the three intermediate groups (expected cumulative risk of ESRD at 10 years in the range of 5-30%), the latest observed cumulative risk of ESRD was substantially higher than both the observed and expected risk at 10 years of follow-up. Despite having few patients in Groups 3-5, >50% of new patients with ESRD after >10 years of follow-up occurred in these groups. Generally, a higher risk of death prior to ESRD was observed in the groups with the highest predicted risk of ESRD. In Risk group 8, where a substantially lower than expected 10-year risk of ESRD was observed, the cumulative 10-year risk of death prior to ESRD was as high as 25.5% and the cumulative risk of the combined end point of death or ESRD was 67.5%, a number that further increased to 83.3% after 10.6 years of follow-up.
When comparing the Kaplan-Meier curves for risk of ESRD, we did not find a significant difference between Groups 1 and 2 (A), neither between Groups 4, 5 and 6 (C) nor between Groups 7 and 8 (D). As described in the Materials and methods section, we merged these groups and the result is shown in Table 3 and Figure 1 . The cumulative risks of death prior to ESRD are shown in Figure 2 .
The results from calculation of 10-year HR of ESRD for all components of the Japanese scoring system are shown in Table 2 . In the adjusted model, we did not find a difference in HR between patients with eGFR >90 versus 60-89 mL/min/1.73m 2 . When comparing patients with eGFR 30-44 versus 45-60 mL/min/1.73m 2 , an adjusted HR of 1.4 (not significant) appeared (data not shown in Table 2 ). An increased risk of ESRD for male gender, as seen in the Japanese IgAN cohort, was not observed in the present study. All other factors in the Japanese scoring system were associated with an increased 10-year HR of ESRD also in the present cohort. The HR of death prior to ESRD in patients with baseline eGFR less than versus higher than 60 mL/min/1.73m 2 adjusted for age and gender was 3.0 (95% confidence interval 1.3-7, P ¼ 0.01). Data on serum albumin were missing in 90 (14%) cases. Fifty-one of these (six with graft loss) would have been classified into a higher risk group if serum albumin was known and were <4.0 g/dL. However, when cumulative risk of ESRD was analysed after exclusion of these patients, only minor differences were found compared to the result observed in the whole cohort.
Discussion
The main finding emerging from the present study is that the Japanese scoring system is applicable to predict 10-year risk of ESRD in Norwegian IgAN patients, indicating that the prognosis of IgAN is similar in Japan and Norway. In the present study, we followed the patients for >10 years and as expected, ESRD continued to occur after 10 years of follow-up. Of interest is the finding that ESRD after >10 years of follow-up appears more frequently in patients with an expected risk after 10 years of 5-30%. As previously found in many other chronic kidney disease cohorts, a low initial eGFR was associated with an increased risk of death prior to ESRD also after adjustment for age and gender [19] [20] [21] . The finding that risk of death prior to ESRD increased with increasing score on the Japanese scoring system of IgAN is therefore no surprise. A major finding in the present study is that patients with a good prognosis, Risk groups 1-2 (A), <5% expected risk of ESRD after 10 years, also has a favourable prognosis regarding risk of ESRD and all-cause mortality after 20 years of follow-up. To what extent did treatment with anti-hypertensive drugs including angiotensin-converting inhibitors or angiotensin receptor blockers among IgAN patients in Risk groups 1-2 (A) contribute to their favourable outcome is not known.
By definition, the Japanese scoring system is applicable to predict risk of ESRD in groups of patients. Since 10-year risk of ESRD is <10% in Risk groups 1-3 (A-B) and >90% in Risk group 9 (E), the scoring system also provides a fairly accurate risk estimate on an individual level in these groups of IgAN patients. In Risk groups 4-8 (C-D), the Japanese scoring system provides a fairly accurate prediction of risk of ESRD in groups but not at an individual level. Therefore, in Risk groups 4-8 (C-D) patients, longitudinal data on GFR and urine protein excretion rate are necessary to determine the long-term prognosis [12, 22, 23] . Recently, the Oxford classification of IgAN was published identifying mesangial hypercellularity, segmental glomerulosclerosis, endocapillary hypercellularity and tubular atrophy/interstitial fibrosis as prognostic factors [24] . Whether prognostic models based on these factors, among Risk groups 4-8 (C-D) patients are better than the Japanese scoring system remains to be investigated.
All prognostic components of the Japanese scoring system, except male gender, were also associated with an increased risk of ESRD in the present study. The Japanese group has previously published another scoring system based on the 7-year data of the same cohort showing male A ¼ Japanese scoring system Risk groups 1-2, B ¼ Japanese scoring system Risk group 3, C ¼ Japanese scoring system Risk groups 4-6, D ¼ Japanese scoring system Risk groups 7-8 and E ¼ Japanese scoring system Risk group 9. gender to be associated with a favourable prognosis [14] . Their explanation for conflicting data regarding the effect of gender on prognosis in IgAN is a formula induced overestimation of women's GFR in their first investigation. The same mechanism might also explain why male gender is not a poor prognostic factor in our study. The Japanese scoring system of IgAN is a relatively complex prognostic model with nine different risk groups. Even with a large cohort such as ours, we could not find significant long-term differences in risk of ESRD between many of the risk groups and our classification of the patients into five different prognostic groups as shown in Table 3 and Figure 1 are definitely more practical. The appropriateness of our simplification with reduction from 9 to 5 risk groups should, however, be validated in other cohorts before this change in the scoring system is generally recommended. Our finding that risk of ESRD after >10 years of follow-up is highest among patients with a moderate expected risk of ESRD is not surprising. Patients with a high risk reach ESRD after <10 years, whereas patients with a favourable prognosis rarely do so even within 20 years of follow-up.
The prognosis of IgAN patients is important as it represents a great number of sick individuals. As IgAN is so common, many reports from different countries have appeared and substantial differences in risk of ESRD have been reported [7] . Also, in the present study, crude ESRD risk was substantially higher in the Norwegian as compared to the Japanese IgAN cohort. However, after adjustment for risk group no difference in prognosis between the Japanese and Norwegian cohort could be found indicating that the prognosis of IgAN is not determined by race or country of residence. The same finding has been reported in previous studies [7, 24] .
The primary strength of the present study is the nature of our cohort; fairly large, unselected/population based, with very long follow-up time and many end points.
The long-term prognosis in IgAN patients is obviously also determined by the quality of care provided in the follow-up period [25, 26] . The follow-up of these patients may be different among countries. We have no data regarding treatment of the patients in our cohort; however, since all patients are diagnosed and usually also followed up by nephrologists, it is a fair assumption that they have been treated according to general and internationally accepted recommendations. Furthermore, as type of treatment is not a prognostic component of the Japanese scoring system, we do not regard missing treatment data as an important weakness of our study. However, it is probably correct to consider the Japanese scoring system as a suitable prognostic tool applicable to well-treated IgAN patients and not to patients following the natural course of this disease.
Minor changes in the comparison between the study of our patients and the patients from Japan should be taken into account. As also suggested by the authors of the Japanese study, we used an estimated GFR formula (the Modification of Diet in Renal Disease formula) that is validated in our own study population [27] . Due to the major difference in mean body mass between the Japanese and the Norwegian population, we believe that the formula (the revised equation for estimated GFR from serum creatinine in Japan) used in the Japanese study would have been less appropriate in our study. We also had to adjust the risk factor microscopic haematuria from 1 to 29 red blood cells per high power field to haemoglobin 1 or 21 on dipstick test, a fact that must be a minor weakness of our study. It is possible that some patients of our cohort could have been scored differently had information regarding number of erythrocytes per high power field been available.
In the Japanese scoring system, as in our study, deaths prior to ESRD have been treated as a censoring event.
Regarding deaths occurring in low-risk patients with no signs of progressive renal insufficiency and no association between the cause of death and IgAN, this approach is probably correct. In high-risk patients, where risk of death is increased due to chronic kidney disease and many of those who died would have developed ESRD had they lived longer, it would probably have been more appropriate to include deaths prior to ESRD in the primary end point. This effect is particularly present in Risk group 8 where a seemingly much better prognosis regarding risk of ESRD than expected can be explained by a high death risk.
In summary, we have shown that the Japanese scoring system is applicable and therefore a suitable prognostic tool to evaluate the prognosis for Norwegian IgAN patients. We have shown that the number of risk groups can be reduced from 9 to 5 without loss of significant prognostic information. In patient groups with moderate risk, long-term risk is substantially >10-year risk of ESRD. A high score in the Japanese scoring system is also associated with a high death risk even after adjustment for age and gender.
